Analytical Data
-
Gene name
GNb1
- Application
-
Alternative Names
GNB1L;GY2;KIAA1645;WDR14;Guanine nucleotide-binding Protein subunit beta-like Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P62873
-
Expression Region
1-340aa
-
AA Sequence
MSELDQLRQEAEQLKNQIRDARKACADATLSQITNNIDPVGRIQMRTRRT LRGHLAKIYAMHWGTDSRLLVSASQDGKLIIWDSYTTNKVHAIPLRSSWV MTCAYAPSGNYVACGGLDNICSIYNLKTREGNVRVSRELAGHTGYLSCCR FLDDNQIVTSSGDTTCALWDIETGQQTTTFTGHTGDVMSLSLAPDTRLFV SGACDASAKLWDVREGMCRQTFTGHESDINAICFFPNGNAFATGSDDATC RLFDLRADQELMTYSHDNIICGITSVSFSKSGRLLLAGYDDFNCNVWDAL KADRAGVLAGHDNRVSCLGVTDDGMAVATGSWDSFLKIWN
-
Molecular Weight
63 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of GNb1 recombinant protein has garnered significant interest due to its potential therapeutic applications in various diseases, particularly in the field of immunology and neurology. GNb1, a monoclonal antibody, targets the extracellular domain of the protein known as the neuronal cell adhesion molecule (NCAM), which plays a crucial role in cell signaling, neural development, and synaptic plasticity. Abnormalities in NCAM interactions have been implicated in neurodegenerative diseases and cancers, making GNb1 a promising candidate for treatment. Recombinant protein technology allows for the production of large quantities of GNb1 with high purity and bioactivity, facilitating deeper studies into its biological functions and mechanisms of action. Researchers have focused on elucidating GNb1's structural properties, binding affinity, and potential to modulate immune responses or neuroprotective effects. Initial preclinical studies have shown promise, suggesting that GNb1 may enhance neuronal survival and improve cognitive function in models of neurodegeneration. Furthermore, understanding the therapeutic potential of GNb1 could lead to novel interventions for conditions such as multiple sclerosis, where NCAM expression is altered. As our knowledge of GNb1 expands, it paves the way for clinical trials aimed at translating these findings into effective therapies, underscoring the importance of recombinant protein studies in the development of innovative treatments for complex diseases.
